Signals
Signals
Signals are grouped clusters of posts about the same development.
How to use: Scan → open one item → check evidence.
ScoreAttention velocity, not truth.MomentumAttention velocity, not truth.
HistoricalSelection window 24hSelection window for ranking; freshness is shown by the Updated badge.Evidence trails in app
Unlock evidence trails
Unlock source trails, evidence timestamps, archive access, and workflow tools.
Flagship sampleUnlocked today
Today’s flagship signal
One free full-detail item per day. Source links included.
Evidence is syncing. Check back shortly.
Signals dashboard
Sorted by impact x momentum. Use the chevron to expand a card. Use the action button for the full drawer.
No investment advice. Research signals and sources only. EarlyNarratives provides informational signals derived from public sources. It does not provide financial, legal, or tax advice.
View mode
Reader mode keeps the list scanable with compact cards and minimal controls.
Filter matches title, tags, and tickers.
New & acceleratingTop signals require cross-source confirmation.
Fresh signals showing clear momentum shifts across sources.
New & accelerating
FDA intensifies scrutiny of compounded GLP-1 drugs and novo nordisk ads
The FDA has ramped up its crackdown on compounded GLP-1 drugs, issuing 30 warning letters to pharmacies. Novo Nordisk faces regulatory scrutiny over its GLP-1 ads, while Intellia is set to restart a heart disease trial.
Updated 2d agoActive span 1d
MomentumCross-source: 3Independent non-social sources mentioning this signal. Cross-source counts are about coverage, not truth.
Primary: 0, Secondary: 3
Gate: independentNonSocial=3; primary=0; secondary=3; rule=(>=2 non-social domains) OR (>=1 primary AND >=1 secondary)
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.9
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
5
PostsCount of items included in the signal cluster for this window.Learn more
5
Details
3 publishers5 posts3 platformsTop source 40%
Evidence: 3 primary
#1 of 6Structural
NewBroad confirmationEmerging confirmation
regulationBiopharma Dive Fierce
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
3
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
5
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
20%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
40%
SourcesNumber of source types represented (e.g., news vs social).Learn more
3
Why now
- The FDA's actions reflect growing concerns about the safety and efficacy of compounded drugs.
- Regulatory scrutiny on advertising practices is crucial for maintaining compliance in the biotech industry.
- The resumption of Intellia's trial highlights the dynamic nature of drug development amidst regulatory challenges.
Why it matters
- Increased FDA scrutiny may impact the availability of compounded GLP-1 drugs.
- Novo Nordisk's advertising practices are under regulatory review, affecting its market strategy.
- Intellia's trial resumption indicates ongoing innovation in heart disease treatments.
Evidence
Evidence is syncing
New & accelerating
FDA Places Partial Hold on PepGen's Muscular Dystrophy Drug Trial
PepGen's phase 2 trial for its muscular dystrophy drug is on partial hold by the FDA due to concerns raised from preclinical data. Analysts suggest the hold is a result of an understaffed FDA, leading to confusion regarding the timing of the decision.
Updated 41h agoActive span 5h
MomentumCross-source: 3Independent non-social sources mentioning this signal. Cross-source counts are about coverage, not truth.
Primary: 0, Secondary: 3
Gate: independentNonSocial=3; primary=0; secondary=3; rule=(>=2 non-social domains) OR (>=1 primary AND >=1 secondary)
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.6
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
4
PostsCount of items included in the signal cluster for this window.Learn more
4
Details
3 publishers4 posts2 platformsTop source 50%
Evidence: 3 primary
#2 of 6Structural
NewBroad confirmationEmerging confirmation
equitiesBiopharma Dive Fierce
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
3
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
4
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
25%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
50%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Why now
- The FDA's decision comes after a review of preclinical data, raising questions about the agency's current operational capacity.
- The timing of the hold is particularly confusing given the recent submission of mouse data in 2024.
- Market reactions are immediate, affecting PepGen's stock performance following the announcement.
Why it matters
- The hold could delay the development of a potentially important treatment for muscular dystrophy.
- Concerns about FDA staffing may highlight broader issues in drug approval processes.
- Investor confidence may be shaken due to the unexpected nature of the hold.
Evidence
Evidence is syncing
New & accelerating
Sanofi acquires sino biopharm’s JAK/ROCK inhibitor for $1.53B
Coverage discusses speculative scenarios around ~$1.5B; treat as market chatter and see linked sources.
Updated 2d agoActive span 12h
MomentumCross-source: 2Independent non-social sources mentioning this signal. Cross-source counts are about coverage, not truth.
Primary: 0, Secondary: 2
Gate: independentNonSocial=2; primary=0; secondary=2; rule=(>=2 non-social domains) OR (>=1 primary AND >=1 secondary)
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.6
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
4
PostsCount of items included in the signal cluster for this window.Learn more
4
Details
3 publishers4 posts3 platformsTop source 50%
Evidence: 2 primary
#3 of 6Structural
NewBroad confirmationEmerging confirmation
Fierce Biotech Fierce
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
3
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
4
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
50%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
50%
SourcesNumber of source types represented (e.g., news vs social).Learn more
3
Why now
- The acquisition comes at a time when innovative therapies are in high demand.
- Sanofi aims to bolster its pipeline with cutting-edge treatments.
- The deal highlights the competitive landscape in the biotech sector.
Why it matters
- This acquisition strengthens Sanofi's position in hematology and immunology.
- The JAK/ROCK inhibitor could address significant unmet medical needs.
- The deal reflects ongoing trends in biotech collaborations and licensing.
Evidence
Evidence is syncing
New & accelerating
Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax. The case was brought by Roiva...
Moderna agrees $950m settlement of mRNA jab litigation Phil.Taylor Wed, 04/03/2026 - 13:19.
Updated 2d agoActive span 6h
MomentumCross-source: 3Independent non-social sources mentioning this signal. Cross-source counts are about coverage, not truth.
Primary: 0, Secondary: 3
Gate: independentNonSocial=3; primary=0; secondary=3; rule=(>=2 non-social domains) OR (>=1 primary AND >=1 secondary)
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.6
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
4
PostsCount of items included in the signal cluster for this window.Learn more
4
Details
3 publishers4 posts2 platformsTop source 50%
Evidence: 3 primary
#4 of 6Structural
NewBroad confirmationEmerging confirmation
mrnapayments
MRNA
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
3
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
4
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
25%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
50%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Evidence
Evidence is syncing
New & accelerating
In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy for Huntington’s disease.
Coverage centers on: In a strikingly blunt briefing, a senior FDA official accused uniQure of pushing “distorted” data to mask a “failed” therapy for Huntington’s disease.
Updated 18h agoActive span 22h
MomentumCross-source: 2Independent non-social sources mentioning this signal. Cross-source counts are about coverage, not truth.
Primary: 0, Secondary: 2
Gate: independentNonSocial=2; primary=0; secondary=2; rule=(>=2 non-social domains) OR (>=1 primary AND >=1 secondary)
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.7
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
2 publishers3 posts3 platformsTop source 67%
Evidence: 1 primary
#5 of 6Structural
NewEmerging confirmation
Fierce Biotech
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
2
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
3
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
67%
SourcesNumber of source types represented (e.g., news vs social).Learn more
3
Evidence
Evidence is syncing
New & accelerating
The FDA is ending a roughly nine-month hiatus of drug-related advisory committee meetings, convening its first session of 2026 to scrutinize a pair of oncolo...
The FDA is ending a roughly nine-month hiatus of drug-related advisory committee meetings, convening its first session of 2026 to scrutinize a pair of oncology applications from AstraZeneca.
Updated 16h agoActive span 0h
MomentumCross-source: 2Independent non-social sources mentioning this signal. Cross-source counts are about coverage, not truth.
Primary: 0, Secondary: 2
Gate: independentNonSocial=2; primary=0; secondary=2; rule=(>=2 non-social domains) OR (>=1 primary AND >=1 secondary)
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.4
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
2 publishers3 posts2 platformsTop source 67%
Evidence: 2 primary
#6 of 6Structural
NewEmerging confirmation
Fierce Biotech
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
2
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
3
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
67%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Evidence
Evidence is syncing
Market chatter
Early chatter with momentum, still building evidence.
Market chatter
Modeling the Impact of RSV Immunization Programs in Western Australia
A recent study models the impact of long-acting monoclonal antibodies and maternal vaccines for RSV immunization in Western Australia. It assesses various programs aimed at reducing RSV-related hospitalizations in children under five years old.
Updated 2d agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts2 platformsTop source 100%
Evidence: 1 specialist
#1 of 5Chatter
NewLow evidenceSingle source
Western Australia
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Why now
- New RSV products like nirsevimab and Abrysvo have recently become available.
- There is a pressing need to evaluate their impact on public health.
- The study provides timely data to inform immunization policy decisions.
Why it matters
- Understanding the effectiveness of RSV immunization programs is crucial for public health.
- The study informs optimal use of new RSV products to reduce hospitalizations.
- Insights from this research can guide future immunization strategies in similar settings.
Evidence
Evidence is syncing
Market chatter
Early Detection of CAR-T-Associated Neurotoxicity via Cytokine Monitoring in Serum
A study shows that monitoring IL-6 levels in CAR-T patients can predict the onset of neurotoxicity, aiding in timely interventions.
Updated 2d agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts2 platformsTop source 100%
Evidence: 1 specialist
#2 of 5Chatter
NewLow evidenceSingle source
Early Detection
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Why now
- The study provides new insights into managing CAR-T therapy complications.
- There is a growing need for effective monitoring strategies in immunotherapy.
- Recent advancements in cytokine measurement techniques support this research.
Why it matters
- Early detection of neurotoxicity can improve patient outcomes in CAR-T therapy.
- Monitoring cytokine levels offers a potential method for timely intervention.
- This research could influence future clinical practices in CAR-T patient management.
Evidence
Evidence is syncing
Market chatter
The impact of neglecting vaccine unwillingness in epidemiology models
A recent study highlights the importance of incorporating vaccine unwillingness into epidemiological models. It suggests that traditional methods may lead to significant errors in predicting disease outcomes.
Updated 15h agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts2 platformsTop source 100%
Evidence: 1 specialist
#3 of 5Chatter
Low evidenceSingle source
Neglecting Vaccine Unwillingness
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Why now
- The ongoing challenges with vaccine uptake necessitate better modeling.
- Recent studies have shown varying rates of vaccine refusal across populations.
- This research provides timely insights as public health strategies evolve.
Why it matters
- Accurate epidemiological models are crucial for public health planning.
- Understanding vaccine refusal can improve disease control strategies.
- Incorporating vaccine willingness may enhance predictive accuracy.
Evidence
Evidence is syncing
Market chatter
Anopheles Salivary Antibody Biomarkers as Surrogate Outcomes in Repellent Trials
A study investigates the use of Anopheles salivary antibody biomarkers as surrogate outcomes to evaluate the effectiveness of topical repellents in Southeast Myanmar. The research highlights the potential of these biomarkers in vector control trials.
Updated 2d agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts2 platformsTop source 100%
Evidence: 1 specialist
#4 of 5Chatter
NewLow evidenceSingle source
Southeast Myanmar
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Why now
- The ongoing threat of mosquito-borne diseases necessitates effective vector control.
- Recent advancements in serological techniques enable better evaluation methods.
- This research aligns with global efforts to combat malaria and other vector-borne diseases.
Why it matters
- The study offers a novel approach to measure the effectiveness of mosquito repellents.
- Understanding antibody responses can enhance vector control strategies.
- This research could lead to improved public health interventions in malaria-endemic regions.
Evidence
Evidence is syncing
Market chatter
Insulin-like Growth Factor-Binding Protein 2 and Adverse Left Ventricular Remodeling After First Myocardial Infarction https://www.medrxiv.org/content/10.648...
Background and Aims: Despite advances in reperfusion and medical therapy, survivors of acute myocardial infarction (AMI) remain at risk for adverse left ventricular remodeling (LVR), a precursor to heart failure.
Updated 36h agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
1 publishers2 posts2 platformsTop source 100%
Evidence: 1 specialist
#5 of 5Chatter
NewLow evidenceSingle source
Growth Factor
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
2
Evidence
Evidence is syncing
Signal
Vinay Prasad, controversial FDA leader, to again depart agency
Vinay Prasad, the controversial director of the FDA's Center for Biologics Evaluation and Research, is set to leave the agency at the end of April. His tenure has been characterized by significant changes to vaccine guidelines and contentious drug rejections, leading to criticism from various advocates.
Updated 11h agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
2.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
5
PostsCount of items included in the signal cluster for this window.Learn more
5
Details
4 publishers5 posts3 platformsTop source 40%
Evidence: 2 primary
#1 of 6Structural
Broad confirmationEmerging confirmation
Biopharma Dive
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
4
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
4
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
20%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
40%
SourcesNumber of source types represented (e.g., news vs social).Learn more
3
Why now
- The announcement comes amid ongoing scrutiny of FDA policies under Prasad.
- His exit follows significant backlash from stakeholders in the biotech community.
- Timing aligns with broader discussions on FDA reform and drug approval processes.
Why it matters
- Prasad's departure could signal a shift in FDA leadership and policy direction.
- His tenure has been contentious, impacting vaccine guidelines and drug approvals.
- The FDA's approach to biologics may change with new leadership.
Evidence
Evidence is syncing
Market chatter
Advancements in cancer research: CRC cell mapping and ALT-targeting
Recent studies have made strides in cancer research, particularly in colorectal cancer and telomere biology. A new framework for CRC cell mapping has been developed, while a model called ALTitude identifies key targets in ALT-driven cancers, enhancing therapeutic strategies.
Updated 29h agoActive span 17h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.1
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
4
PostsCount of items included in the signal cluster for this window.Learn more
4
Details
1 publishers4 posts1 platformsTop source 100%
Evidence: 1 specialist
#2 of 6Chatter
NewEmerging confirmationSingle source
Deep Learning Enabled
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Evidence mix: 2 sampled posts across 1 source types.
- Origins: 1 unique origin domains across the allowed sources.
Why it matters
- Understanding cancer mechanisms can lead to better treatment strategies.
- Identifying new therapeutic targets like SMARCAL1 may improve outcomes for patients with aggressive cancers.
- Integrating patient-specific data enhances the relevance of research findings.
Evidence
Evidence is syncing
Signal
Insights into motor control: Anticipation, intention prediction, and sensory feedback
Recent research highlights the neural mechanisms of motor control, focusing on anticipation, intention prediction, and sensory feedback integration.
Updated 29h agoActive span 1h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.2
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
3
PostsCount of items included in the signal cluster for this window.Learn more
3
Details
2 publishers3 posts1 platformsTop source 67%
Evidence: 2 specialist
#3 of 6Structural
NewEmerging confirmation
Reciprocal Fronto
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
2
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
67%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Recent studies provide new insights into the neural basis of motor functions.
- Advancements in technology allow for better analysis of motor intentions.
- The need for improved rehabilitation strategies is increasingly recognized.
Why it matters
- Understanding motor control mechanisms can enhance rehabilitation technologies.
- Insights into sensory feedback integration may improve adaptive motor recovery systems.
- Decoding motor intentions can lead to more responsive assistive devices.
Evidence
Evidence is syncing
Signal
Exploring personalized neuromodulation in clinical trials
Recent clinical trials have focused on personalized neuromodulation techniques for chronic pain and cognitive enhancement.
Updated 2d agoActive span 21h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.0
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
2
PostsCount of items included in the signal cluster for this window.Learn more
2
Details
2 publishers2 posts1 platformsTop source 50%
Evidence: 2 specialist
#4 of 6Structural
New
personalizing
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
2
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
2
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
50%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Why now
- Recent advancements in brain imaging and stimulation technologies enable innovative trials.
- There is a rising interest in personalized medicine approaches in neurology.
- Understanding individual neural dynamics can improve therapeutic strategies.
Why it matters
- Personalized approaches may enhance treatment efficacy for chronic pain.
- Real-time adjustments in brain stimulation could lead to better cognitive outcomes.
- These studies contribute to the growing field of neuromodulation and its applications.
Evidence
Evidence is syncing
Market chatter
Opinion/decision on a Paediatric investigation plan (PIP): Ultomiris, ravulizumab, decision type: PM: decision on the application for modification of an agre...
Opinion/decision on a Paediatric investigation plan (PIP): Zegalogue, Dasiglucagon, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrine disorders, PIP number: EMA/PE/0000181174.
Updated 19h agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.5
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
11
PostsCount of items included in the signal cluster for this window.Learn more
11
Details
1 publishers11 posts1 platformsTop source 100%
Evidence: 1 specialist
#5 of 6Chatter
NewAcceleratingEmerging confirmationSingle source
Ema What
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Evidence
Evidence is syncing
Market chatter
EMA/PE/0000223498
EMA/PE/0000222938.
Updated 42h agoActive span 0h
Momentum
ScoreOverall signal strength in the selected window; higher means more evidence/consistency, not a prediction.Learn more
1.3
Momentum 24hChange in signal activity over the last 24 hours; higher means accelerating attention, not performance.Learn more
8
PostsCount of items included in the signal cluster for this window.Learn more
8
Details
1 publishers8 posts1 platformsTop source 100%
Evidence: 1 specialist
#6 of 6Chatter
NewEmerging confirmationSingle source
ema
OriginsDistinct origin sources contributing to this signal; higher means broader origin coverage.Learn more
1
PublishersDistinct publishers/accounts observed; higher means broader publisher participation.Learn more
1
Dup ratioShare of near-duplicate items in the cluster; higher can indicate repetition or amplification.Learn more
0%
Top origin sharePortion of items from the top origin; higher means more concentration.Learn more
100%
SourcesNumber of source types represented (e.g., news vs social).Learn more
1
Evidence
Evidence is syncing